Crooke, Stephen N.
Ovsyannikova, Inna G.
Poland, Gregory A.
Kennedy, Richard B.
Funding for this research was provided by:
National Institute of Allergy and Infectious Diseases (AI089859, AI132348)
Article History
Received: 14 December 2018
Accepted: 27 August 2019
First Online: 13 September 2019
Ethics approval and consent to participate
: Not applicable.
: Not applicable.
: Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, Dynavax, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents related to vaccinia and measles peptide vaccines. Dr. Kennedy holds a patent related to vaccinia peptide vaccines. Dr. Kennedy has received research funding from Merck Research Laboratories to study waning immune responses to mumps vaccine. These activities have been reviewed by the Mayo Clinic Conflict of Interest Review Board and are conducted in compliance with Mayo Clinic Conflict of Interest policies. All other authors declare no competing interests.